← Back to Search

Procedure

PXL-330 Platinum device for crosslinking with Peschke riboflavin solution for Keratoconus

Phase 1 & 2
Waitlist Available
Led By S. Lance Forstot, M.D.
Research Sponsored by Colorado Eye Consultants/Cornea Consultants of Colorado
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Summary

This trial will test a new machine that uses a different method to do cross-linking, to see if it is effective and safe.

Eligible Conditions
  • Pellucid Marginal Corneal Degeneration
  • Keratoconus
  • Corneal Ectasia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Corrected distance visual acuity
Secondary outcome measures
Keratometry
Uncorrected visual acuity

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Pulsed, AcceleratedExperimental Treatment1 Intervention
5 mW, 10 sec on, 10 sec off, 24 minutes of illumination Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Group II: ConventionalActive Control1 Intervention
4 mW, 10 sec on, 10 sec off, 30 minutes of illumination Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
2020
Completed Phase 1
~200

Find a Location

Who is running the clinical trial?

Colorado Eye Consultants/Cornea Consultants of ColoradoLead Sponsor
S. Lance Forstot, M.D.Principal InvestigatorColorado Eye Consultants/Corneal Consultants of Colorado
~59 spots leftby Jul 2025